Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?
Sarcoidosis vasculitis and diffuse lung diseases · 10.12.2024 · 41 (4) · e2024036-e2024036
DOI: 10.36141/svdld.v41i4.15873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 10.12.2024. Verfasst von Misbah Nizamani. Beteiligte Einrichtung: Dow Medical College, DUHS. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Sarcoidosis is a multi-system disorder characterized by the formation of non-caseating granulomas. It is a disorder of unknown etiology. Interferon-induced sarcoidosis is a well-known phenomenon. However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.
Schlagwörter
Autor:innen und Institutionen
- Dow Medical College, DUHS.
Zitieren
APA
Nizamani, M. (2024). Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?. Sarcoidosis vasculitis and diffuse lung diseases, 41(4), e2024036-e2024036. https://doi.org/10.36141/svdld.v41i4.15873
Vancouver
Nizamani M. Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?. Sarcoidosis vasculitis and diffuse lung diseases. 2024;41(4):e2024036-e2024036. doi:10.36141/svdld.v41i4.15873
BibTeX
@article{Nizamani2024,
author = {Nizamani, Misbah},
title = {Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2024},
volume = {41},
number = {4},
pages = {e2024036--e2024036},
doi = {10.36141/svdld.v41i4.15873}
}
EUVIMED